Paclitaxel-loaded niosomes in combination with metformin: development, characterization and anticancer potentials.

Aim: This study aims to assess the efficacy of free and niosomes-loaded paclitaxel combined with the anti-diabetic drug metformin. Methods: Paclitaxel was successfully encapsulated in all niosome formulations, using microfluidic mixing, with a maximum encapsulation efficiency of 11.9%. Results: The half maximal inhibitory concentration (IC50) for free paclitaxel in T47D cells was significantly reduced from 0.2 to 0.048 mg/ml when combined with metformin 40 mg. The IC50 of paclitaxel was significantly reduced when loaded in niosomes to less than 0.06 mg/ml alone or with metformin. Conclusion: Paclitaxel combination (free or loaded into niosomes) with metformin significantly improved the anticancer efficacy of paclitaxel, which can serve as a method to reduce the paclitaxel dose and its associated side effects.

Citation

Taqwa Al-Kofahi, Bahaa Altrad, Haneen Amawi, Alaa A Aljabali, Yousef M Abul-Haija, Mohammad A Obeid. Paclitaxel-loaded niosomes in combination with metformin: development, characterization and anticancer potentials. Therapeutic delivery. 2024 Feb;15(2):109-118

Mesh Tags

Substances

PMID: 38214106

search → result